Page 39 - Confidence Interval News Today

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma - read this article along with other careers information, tips and advice on BioSpace

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients

Internal measure of potential market loss brings bank in line with the likes of JP Morgan and BofA

Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival (mPFS) of 35.7 months (Hazard Ratio [HR] 0.58; 95% Confidence Interval [CI]: 25.8 to 44.0; n=179), compared to 19.2 months in ...

16.05.2022 - Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from ... Seite 1

Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a prot

Sarclisa (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy Latest results of

1. Patients receiving the fourth dose of BNT162b2 (Pfizer-BioNTech) showed reduced rates of symptomatic Covid-19 infection and hospitalization compared to their matched control over 30 days of follow-up. 2. Patients receiving the fourth dose of BNT162b2 were shown to have a lower rate of death compared to their matched control over 30 days of follow-up. […]

1. The Canadian Syncope Risk Score was superior when compared to the Osservatorio Epidemiologico della Sincope nel Lazio (OESIL) score in identifying patients at low risk for serious outcomes. 2. The clinical utility of the Canadian Syncope Risk Score (CSRS) still remains uncertain given the influence of clinician classification of syncope at ED discharge affecting […]